Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’

Lead Research Organisation: University of Cambridge

Abstract

The mission of the Cambridge Stem Cell Institute (CSCI) is to transform the prevention, diagnosis and treatment of disease through a deep understanding of the mechanisms regulating normal and pathological stem cells. Outstanding research scientists, technology specialists and doctors work side-by-side in a world-leading centre of excellence. In 2018 all the members of CSCI, currently based at several sites across the University, will come together in a purpose-built building situated in the heart of the University’s Biomedical Campus.
Together, we will apply pioneering methods and technologies to respond to three
driving questions:
• How do normal stem cells behave in healthy tissues?
• How do abnormal stem cells contribute to disease?
• How can we use this knowledge to deliver stem cell based treatments?

Technical Summary

Stem and progenitor cells are essential for the maintenance of metazoan tissues. Their dysfunction underlies diverse human diseases and their manipulation provides enormous therapeutic possibilities. The Cambridge Stem Cell Institute (CSCI) is a world-leading centre for stem cell research. Its mission is to transform the prevention, diagnosis and treatment of disease through a deep understanding of the mechanisms regulating stem and progenitor cells, both normal and pathological.
In 2018 CSCI investigators will come together in a new purpose-built building on the Cambridge Biomedical Campus adjacent to Addenbrookes Hospital. A key strategy is to embed biological, clinical and physical scientists operating across disparate tissues and at multiple scales, thus allowing commonalities and differences to be explored in an cohesive and inter-disciplinary manner. A network of affiliated PIs will provide bridges to basic and disease-focused institutes throughout Cambridge and will ensure that CSCI represents the heart of a vibrant stem cell community. Importantly a critical mass of clinician scientists will create synergistic interactions between basic scientists and those driven by disease-focused questions, thus ensuring that CSCI is fully integrated with its clinical environment and empowered to pursue its translational goals.

Organisations

Publications

10 25 50
 
Title A Pattern for Progress (2019) by Harold Offeh 
Description Harold Offeh brought together people living with multiple sclerosis (MS) and their carers, with scientists researching this neurological disease. Through a series of ceramic workshops, participants shared their experiences of MS and produced the tiles converted into a vinyl 'wallpaper' by the artist. An accompanying film captures their stories. Commissioned by the Wellcome-MRC Cambridge Stem Cell Institute Public Engagement programme, in partnership with the MS Society and Kettle's Yard. 
Type Of Art Artwork 
Year Produced 2019 
Impact Non known 
URL https://www.haroldoffeh.com/projects/a-pattern-for-progress
 
Title Let The Eye Be Substituted For The Sun (2019) by Victoria Morton 
Description This work was created through time spent in laboratories talking to scientists about their research. The artist was fascinated by the technology used to cultivate and visualise cells at the microscopic level, and hopes the artwork reflects these complex processes, whilst allowing the mind to wander and focus at the same time. Commissioned by the Wellcome-MRC Cambridge Stem Cell Institute Public Engagement programme for the Jeffrey Cheah Biomedical Centre, in partnership with Kettle's Yard. 
Type Of Art Artwork 
Year Produced 2019 
Impact None known 
URL https://www.stemcells.cam.ac.uk/about-us/jcbc/art/victoria-morton
 
Title The Night the Mountains Moved (2020) and Futuramic Unknown (2020) by Anna Brownsted 
Description Anna Brownsted created this work in response to a project connecting Blood Cancer UK patient ambassadors and stem cell researchers. Together, they explored experiences of 'the unknown' in living with blood cancer, the challenges of research, and the Covid-19 pandemic. The artist drew inspiration for this collage from animations created by project participants using photographs from National Geographic published in 1960 - the year Blood Cancer UK was founded - and compiled in the accompanying film Futuramic Unknown. Commissioned by the Wellcome-MRC Cambridge Stem Cell Institute Public Engagement programme, in partnership with Blood Cancer UK and Kettle's Yard. 
Type Of Art Artwork 
Year Produced 2020 
Impact Not known 
URL https://www.annabrownsted.com/the-night-the-mountains-moved-https%3A/www.stemcells.cam.ac.uk/about-u...
 
Description (ChRONAM-H) - Chromatin Regulation Of Normal And Malignant Haematopoiesis
Amount € 212,934 (EUR)
Funding ID 886474 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 09/2020 
End 09/2022
 
Description (HARMONY PLUS) - HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY - PLUS
Amount € 11,882,669 (EUR)
Funding ID 945406 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 09/2020 
End 09/2023
 
Description (NSC-Reconstruct) - Novel Strategies for Cell-based Neural Reconstruction
Amount € 8,169,231 (EUR)
Funding ID 874758 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2020 
End 12/2023
 
Description BRAINS FOR DEMENTIA RESEARCH STEM CELL AND FIBROBLAST RESOURCE
Amount £50,000 (GBP)
Organisation Newcastle University 
Sector Academic/University
Country United Kingdom
Start 03/2020 
End 09/2022
 
Description Bioengineering The iLUNGs BBSRC
Amount £193,789 (GBP)
Funding ID BB/W014564/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 01/2022 
End 01/2024
 
Description Biogenesis and bioengineering of human platelets
Amount £593,451 (GBP)
Funding ID 219472/A/19/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2020 
End 02/2025
 
Description CHARACTERISING THE ROLE OF TRANSLATED MICROPEPTIDES IN DIFFU
Amount £9,931 (GBP)
Funding ID Seedcorn2020\100305 
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2021 
End 03/2022
 
Description CHARACTERISING THE ROLE OF TRANSLATED MICROPEPTIDES IN DIFFUSE LARGE B-CELL LYMPHOMA
Amount £19,628 (GBP)
Organisation British Society for Haematology 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2022 
End 03/2022
 
Description CHROMATIN (MIS) REGULATION OF LINEAGE COMMITMENT IN LEUKEMIA
Amount £129,310 (GBP)
Funding ID GENE REGULATORY COMPLEXES AND NETWORKS REGULATED BY THE ERG 
Organisation European Hematology Association (EHA) 
Sector Charity/Non Profit
Country Netherlands
Start 09/2021 
End 09/2024
 
Description COLLABORATION: ASTRAZENECA UK LIMITED - ELUCIDATING NON-GENE
Amount £378,785 (GBP)
Funding ID 10046922 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 08/2021 
End 08/2023
 
Description COLLABORATION: ASTRAZENECA UK LTD - THE MOLECULAR PATHOGENES
Amount £379,164 (GBP)
Funding ID 10047580 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 09/2021 
End 03/2024
 
Description COLLABORATION: GENOME RESEARCH LIMITED - DECIPHERING MYELOID
Amount £494,925 (GBP)
Funding ID 10115 
Organisation Genome Research Ltd 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2020 
End 04/2024
 
Description COLLABORATION: GENOME RESEARCH LIMITED - IMMUNO-ONCOLOGY TAR
Amount £50,000 (GBP)
Organisation Genome Research Ltd 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2021 
End 04/2024
 
Description COLLABORATION: NADACE AGING BIOLOGY FOUNDATION EUROPE - SING
Amount £52,779 (GBP)
Funding ID Single cell profiling of open chromatin status in human bone marrow mononuclear cells from young and old donors". 
Organisation Aging Biology Foundation Europe 
Sector Private
Country Czech Republic
Start 03/2022 
End 03/2023
 
Description COLLABORATION: UNIVERSITY OF NEWCASTLE UPON TYNE (/FB ALZHEI
Amount £500,000 (GBP)
Organisation Newcastle University 
Sector Academic/University
Country United Kingdom
Start 03/2020 
End 09/2022
 
Description COLLABORATION: UNIVERSITY OF YORK (FB MRC) - HUMAN BLOOD STE
Amount £634,916 (GBP)
Funding ID MR/V005502/1 
Organisation University of York 
Sector Academic/University
Country United Kingdom
Start 09/2020 
End 09/2023
 
Description COLLABORATION: WEIZMANN INSTITUTE OF SCIENCE - CIRCADIAN RHY
Amount £36,837 (GBP)
Funding ID COLLABORATION: WEIZMANN INSTITUTE OF SCIENCE - CIRCADIAN RHY 
Organisation American Committee for the Weizmann Institute of Science 
Sector Charity/Non Profit
Country United States
Start 09/2020 
End 09/2022
 
Description COMBATTING PROGRESSION IN MS - WHEN AND HOW?
Amount £1,850,000 (GBP)
Funding ID 132 
Organisation Multiple Sclerosis Society 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2021 
End 03/2025
 
Description CONSORTIUM: H2020 IMI2 - HEALTHCARE ALLIANCE FOR RESOURCEFUL
Amount £80,357 (GBP)
Funding ID 945406 
Organisation IMI Europe Limited 
Sector Public
Country United Kingdom
Start 09/2020 
End 09/2023
 
Description CRE BHF
Amount £13,800 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 07/2022
 
Description Cambridge Stem Cell Institute
Amount £3,286,966 (GBP)
Funding ID 203151/A/16/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2022 
End 06/2024
 
Description Cell fate regulation during gastrulation in humans and pigs
Amount £79,145 (GBP)
Funding ID BB/S001816/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2018 
End 12/2022
 
Description Cellular and molecular characterisation of epithelial tumour initiation
Amount £1,613,965 (GBP)
Funding ID DCRPGF\100010 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2021 
End 02/2027
 
Description DECIPHERING THE GENOMICS OF AGGRESSIVE NON-HODGKIN LYMPHOMA
Amount £2,142,349 (GBP)
Funding ID RCCFEL\100072 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2021 
End 03/2027
 
Description DECIPHERING THE MECHANISMS OF EPIGENETIC
Amount £300,000 (GBP)
Funding ID 222800 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2021 
End 06/2025
 
Description DEVELOPING CELL MODELS TO INTERROGATE MECHANICAL SIGNALLING
Amount £24,216 (GBP)
Funding ID 21.07(d) 
Organisation University of Cambridge 
Department Isaac Newton Trust
Sector Academic/University
Country United Kingdom
Start 07/2021 
End 01/2022
 
Description Exploiting stage-specific dependencies on RNA helicases in MYC-driven lymphoma"
Amount £264,618 (GBP)
Funding ID KKL1398 
Organisation The Kay Kendall Leukaemia Fund 
Sector Academic/University
Country United Kingdom
Start 04/2021 
End 04/2024
 
Description FIRST STEPS TOWARDS CHEMOTHERAPY-FREE TREATMENT OF SGK1-MUTA
Amount £227,078 (GBP)
Funding ID KKL1445 
Organisation The Kay Kendall Leukaemia Fund 
Sector Academic/University
Country United Kingdom
Start 01/2022 
End 04/2023
 
Description GENE REGULATORY COMPLEXES AND NETWORKS REGULATED BY THE ERG
Amount £35,000 (GBP)
Funding ID LT100 
Organisation Lady Tata Memorial Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2020 
End 09/2021
 
Description GENE REGULATORY COMPLEXES AND NETWORKS REGULATED BY THE ERG
Amount £88,503 (GBP)
Funding ID CHROMATIN (MIS) REGULATION OF LINEAGE COMMITMENT IN LEUKEMIA 
Organisation European Hematology Association (EHA) 
Sector Charity/Non Profit
Country Netherlands
Start 09/2020 
End 09/2022
 
Description GENE REGULATORY NETWORKS IN NORMAL AND MALIGNANT HEMATOPOIES
Amount £248,508 (GBP)
Funding ID HR20-00871 
Organisation University of Navarra 
Sector Academic/University
Country Spain
Start 12/2020 
End 11/2023
 
Description GENERATING A GLOBAL VIEW OF CELL LINEAGE TREES DURING EARLY
Amount £300,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2020 
End 03/2023
 
Description GENERATION OF TISSUE-RESIDENT CARDIAC MACROPHAGES FROM HUMAN
Amount £9,500 (GBP)
Funding ID 111882 
Organisation ACT 
Sector Charity/Non Profit
Country United States
Start 03/2021 
End 02/2022
 
Description Generating platelets in vitro for the clinic: optimisation and added clinical efficacy
Amount £474,809 (GBP)
Funding ID MR/V005413/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 08/2020 
End 09/2023
 
Description HE ROLE OF A COMMON FACTOR V HAPLOTYPE IN PROTECTING
Amount £19,775 (GBP)
Organisation British Society for Haematology 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2021 
End 09/2022
 
Description Human Cell Atlas - development atlas extension
Amount £119,697 (GBP)
Funding ID 221052/C/20/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2020 
End 11/2022
 
Description IDENTIFICATION AND FUNCTIONAL CHARACTERISATION OF CORE METAB
Amount £244,219 (GBP)
Funding ID KKL1440 
Organisation The Kay Kendall Leukaemia Fund 
Sector Academic/University
Country United Kingdom
Start 06/2022 
End 06/2023
 
Description INVESTIGATION OF GENETIC VULNERABILITIES OF DNMT3A-MUTANT PR
Amount £248,683 (GBP)
Funding ID 21006 
Organisation Blood Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2021 
End 12/2023
 
Description Improving haematopoietic reconstitution in blood stem cell transplantation
Amount £634,921 (GBP)
Funding ID MR/V005421/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2020 
End 09/2023
 
Description Improving haematopoietic reconstitution in blood stem cell transplantation procedures through the regulation of stem cells and their niches
Amount £634,921 (GBP)
Funding ID MR/V005421/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 08/2020 
End 09/2023
 
Description Junior Research Grant
Amount € 100,000 (EUR)
Funding ID RG65 
Organisation European Hematology Association (EHA) 
Sector Charity/Non Profit
Country Netherlands
Start 09/2020 
End 09/2022
 
Description KING'S COLLEGE FELLOW - DR MYFANWY HILL
Amount £250,000 (GBP)
Funding ID Loke Fellowship 
Organisation King's College 
Sector Academic/University
Country United States
Start 01/2021 
End 12/2025
 
Description MINUTE 21.39(B) NICHE-DEPENDENCIES AND DRUG RESISTANCE IN B
Amount £21,154 (GBP)
Funding ID MINUTE 21.39(B) 
Organisation University of Cambridge 
Department Isaac Newton Trust
Sector Academic/University
Country United Kingdom
Start 03/2021 
End 12/2022
 
Description Mechanisms of adhesion-dependent haematopoietic transdetermination
Amount £575,124 (GBP)
Funding ID MR/T028343/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 06/2020 
End 07/2023
 
Description Microenvironment Regulation of Zika Virus Susceptibility in Human Brain Development and Malignant Glioma
Amount £861,960 (GBP)
Funding ID 223011 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2022 
End 04/2026
 
Description Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis
Amount £2,379,992 (GBP)
Funding ID 220379/B/20/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2020 
End 11/2025
 
Description Newton Trust MS - In Full Force: Investigating the mechanica
Amount £65,770 (GBP)
Organisation University of Cambridge 
Department Isaac Newton Trust
Sector Academic/University
Country United Kingdom
Start 02/2022 
End 06/2024
 
Description Patterning the embryo, one signalling
Amount £300,000 (GBP)
Funding ID 224070 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 02/2026
 
Description REGENERATIVE MEDICINE APPLICATIONS OF CHOLANGIOCYTE ORGANOID
Amount £1,530,439 (GBP)
Funding ID MR/V023004/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2021 
End 09/2025
 
Description ROLE OF MECHANICAL SIGNALLING AT THE NUCLEAR ENVELOPE IN PLU
Amount £645,393 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 03/2022 
End 09/2024
 
Description ROSETREES TRUST - HUMAN ORGANOID MODELLING OF NEUROGENETIC E
Amount £37,500 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2021 
End 09/2024
 
Description Role of mechanical signalling at the nuclear envelope in pluripotent stem cell differentiation
Amount £645,392 (GBP)
Funding ID BB/W000423/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2021 
End 09/2024
 
Description SINGLE-CELL ANALYSIS DISSECTS CLONAL SPECIFIC CHROMATIN STAT
Amount £740,000 (GBP)
Funding ID NAFR12_1011 
Organisation Academy of Medical Sciences (AMS) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2021 
End 03/2023
 
Description STROMAL NICHE ORCHESTRATES EPITHELIAL CELL BEHAVIOUR IN EARL
Amount £23,571 (GBP)
Funding ID 21.07(a) 
Organisation University of Cambridge 
Department Isaac Newton Trust
Sector Academic/University
Country United Kingdom
Start 03/2021 
End 04/2022
 
Description Structural studies of the ATRX-DAXX chromatin remodeller complex and its role in heterochromatin and telomere maintenance
Amount £379,655 (GBP)
Funding ID 223008 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2022 
End 01/2026
 
Description TBC
Amount £19,480 (GBP)
Funding ID 106325 
Organisation The Evelyn Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 01/2022
 
Description THE MECHANICS OF OESOPHAGEAL TUMOUR FORMATION
Amount £20,000 (GBP)
Funding ID RGS\R1\211424 
Organisation The Royal Society 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2021 
End 03/2022
 
Description TOWARDS AN EARLY DETECTION PROGRAMME FOR MYELOID MALIGNANCIE
Amount £665,791 (GBP)
Funding ID EDDCPJT\100010 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2021 
End 08/2025
 
Description Targeting remodelling of lung stem and niche cells: lessons from regeneration to disease
Amount £2,107,440 (GBP)
Funding ID 221857 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2021 
End 06/2026
 
Description The cellular immune response to B.1.1.7 variant COVID-19 deciphered by single cell
Amount £37,300 (GBP)
Funding ID MR/W014556/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2021 
End 07/2021
 
Description UK Human Developmental Biology Initiative
Amount £133,303 (GBP)
Funding ID 215116/A/18/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2019 
End 09/2024
 
Description UPSCALED HEPATOCYTE CULTURE FOR LIVER CELL THERAPY
Amount £42,841 (GBP)
Organisation The Evelyn Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2021 
End 10/2022
 
Description Understanding of metabolic and acetyl state in hPSC for large scale production
Amount £103,929 (GBP)
Funding ID BB/W510385/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2021 
End 09/2025
 
Description University of Sheffield (f/b Cystic Fibrosis Trust)
Amount £20,000 (GBP)
Organisation University of Sheffield 
Sector Academic/University
Country United Kingdom
Start 01/2021 
End 12/2026
 
Description Ana Cvejic - EBI 
Organisation EMBL European Bioinformatics Institute (EMBL - EBI)
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Ana Cvejic - Collaborative project
Collaborator Contribution Collaborative research with Moritz Gerstung of the EMBL European Bioinformatics Institute.
Impact Outputs expected
Start Year 2020
 
Description Ana Cvejic - Wellcome Sanger Institute 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI Ana Cvejic - Collaborative project
Collaborator Contribution Collaboration with Omer Ali Bayraktar at the Wellcome Trust Sanger Institute.
Impact Outputs expected
Start Year 2020
 
Description Brian Hendrich - University of Dundee 
Organisation University of Dundee
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Brian Hendrich - joint grant application
Collaborator Contribution Joint grant application with Greg Findlay of the University of Dundee
Impact Grant application outcome unknown
Start Year 2020
 
Description Brian Hendrich - University of Edinburgh 
Organisation University of Edinburgh
Department Centre for Discovery Brain Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Brian Hendrich - joint grant application
Collaborator Contribution Joint grant application with John Mason of the University of Edinburgh's Centre for Discovery Brain Sciences.
Impact Grant application outcome unknown
Start Year 2020
 
Description Brian Hendrich - University of Oslo 
Organisation University of Oslo
Department Institute of Basic Medical Sciences
Country Norway 
Sector Academic/University 
PI Contribution CSCI PI Brian Hendrich - joint grant application
Collaborator Contribution Joint grant application with Gareth Sullivan of the University of Oslo's Institute of Basic Medical Sciences.
Impact Grant application outcome unknown
Start Year 2020
 
Description Brian Hendrich - Washington University in St. Louis 
Organisation Washington University in St Louis
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CSCI PI Brian Hendrich - joint grant application
Collaborator Contribution Joint grant application with Sabine Dietman of the Washington University (St Louis) School of Medicine.
Impact Application outcome unknown
Start Year 2020
 
Description Brian Huntly - Babraham Institute 
Organisation Babraham Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Brian Huntly - Collaborative project
Collaborator Contribution Collaborative project with Wolf Reik of Babraham Institute's Epigenetics lab.
Impact Outputs expected 2021
Start Year 2020
 
Description Brian Huntly - Centre for Genomic Regulation 
Organisation Centre for Genomic Regulation (CRG)
Country Spain 
Sector Academic/University 
PI Contribution CSCI PI Brian Huntly - Collaborative project
Collaborator Contribution Collaboration with Marc Marti-Renom of the Centre for Genomic Regulation
Impact Outcomes expected 2021
Start Year 2020
 
Description Brian Huntly - Institut Gustave Roussy 
Organisation Gustave-Roussy Institute
Country France 
Sector Academic/University 
PI Contribution CSCI PI Brian Huntly - Collaborative project
Collaborator Contribution Collaboration with Thomas Mercher of l'Institut Gustave Roussy
Impact Outcomes expected 2021
Start Year 2020
 
Description Brian Huntly - University of Navarra 
Organisation University of Navarra Clinic
Country Spain 
Sector Hospitals 
PI Contribution CSCI PI Brian Huntly - Collaborative project and joint grant application
Collaborator Contribution Collaboration and joint grant application with Felipe Prosper of University of Navarra Clinic.
Impact Outcomes expected later in 2021
Start Year 2020
 
Description CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution Project leadership. Design of new murine models of myeloid and malignancy.
Collaborator Contribution Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models
Impact Mouse models are still in development.
Start Year 2022
 
Description CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis 
Organisation Medical Research Council (MRC)
Country United Kingdom 
Sector Public 
PI Contribution Project leadership. Design of new murine models of myeloid and malignancy.
Collaborator Contribution Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models
Impact Mouse models are still in development.
Start Year 2022
 
Description CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Project leadership. Design of new murine models of myeloid and malignancy.
Collaborator Contribution Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models
Impact Mouse models are still in development.
Start Year 2022
 
Description CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Project leadership. Design of new murine models of myeloid and malignancy.
Collaborator Contribution Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models
Impact Mouse models are still in development.
Start Year 2022
 
Description CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis 
Organisation University of York
Country United Kingdom 
Sector Academic/University 
PI Contribution Project leadership. Design of new murine models of myeloid and malignancy.
Collaborator Contribution Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models
Impact Mouse models are still in development.
Start Year 2022
 
Description CSCI PI Dan Hodson - Collaborative project 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Collaboration with Andrew Mortlock at AstraZeneca Cambridge involving the DIRECT Trial - a molecular profiling study in aggressive B cell lymphoma
Collaborator Contribution .
Impact .
Start Year 2020
 
Description CSCI PI Fotios Sampaziotis - 
Organisation University of Cambridge
Department Cambridge Infectious Diseases
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration on repurposing drug for COVID19
Collaborator Contribution Collaboration on repurposing drug for COVID19
Impact 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology
Start Year 2021
 
Description CSCI PI Fotios Sampaziotis - 
Organisation University of Cambridge
Department Clinical Pharmacology Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration on repurposing drug for COVID19
Collaborator Contribution Collaboration on repurposing drug for COVID19
Impact 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology
Start Year 2021
 
Description CSCI PI Fotios Sampaziotis - 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration on repurposing drug for COVID19
Collaborator Contribution Collaboration on repurposing drug for COVID19
Impact 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology
Start Year 2021
 
Description CSCI PI Fotios Sampaziotis - 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration on repurposing drug for COVID19
Collaborator Contribution Collaboration on repurposing drug for COVID19
Impact 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology
Start Year 2021
 
Description CSCI PI Fotios Sampaziotis - 
Organisation University of Vienna
Country Austria 
Sector Academic/University 
PI Contribution Collaboration on repurposing drug for COVID19
Collaborator Contribution Collaboration on repurposing drug for COVID19
Impact 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology
Start Year 2021
 
Description CSCI PI Walid Khaled - Collaborative project 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution .Collaboration with AstraZeneca involving part-time PhD studentship (AZ employee) based at Pharmacology
Collaborator Contribution .
Impact Collaboration with AstraZeneca involving Part-time PhD studentship (AZ employee) based at Pharmacology.
Start Year 2021
 
Description Cedric Ghevaert - AstraZeneca 
Organisation AstraZeneca
Department AstraZeneca Sweden
Country Sweden 
Sector Private 
PI Contribution CSCI PI Cedric Ghevaert - Collaborative project
Collaborator Contribution Collaboration with Ryan Hicks at AstraZeneca Sweden involving university stem cells.
Impact Outputs and outcomes expected 2021
Start Year 2019
 
Description Cedric Ghevaert - Rockend, LTD 
Organisation University of Cambridge
Department Milner Therapeutics Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Cedric Ghevaert - Collaborative project
Collaborator Contribution Collaboration with Shaun Foy and Rodger Novak of Rockend, Ltd, titled "Production of platelet-like particles in vitro for therapeutics."
Impact Outputs and outcomes expected 2021
Start Year 2019
 
Description Cedric Ghevaert - University College London - University of Edinburgh 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Cedric Ghevaert - Collaborative project
Collaborator Contribution Collaboration with Wasim Qaseem of University College London and Stuart Forbes of the University of Edinburgh entitled "Immunology Project (UKRMP to UCL) - Universal cells to overcome HLA barriers in regenerative medicine".
Impact Outputs and outcomes expected 2021
Start Year 2019
 
Description Cedric Ghevaert - University College London - University of Edinburgh 
Organisation University of Edinburgh
Department MRC Centre for Regenerative Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Cedric Ghevaert - Collaborative project
Collaborator Contribution Collaboration with Wasim Qaseem of University College London and Stuart Forbes of the University of Edinburgh entitled "Immunology Project (UKRMP to UCL) - Universal cells to overcome HLA barriers in regenerative medicine".
Impact Outputs and outcomes expected 2021
Start Year 2019
 
Description Cedric Ghevaert - University of Bristol 
Organisation University of Bristol
Department School of Physiology, Pharmacology and Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Cedric Ghevaert - Collaborative project
Collaborator Contribution Collaboration with Alastair Poole of University of Bristol titled "Biogenesis and Bioengineering of Human Platelets."
Impact Outputs and outcomes expected 2021
Start Year 2019
 
Description Cedric Ghevaert - University of Cambridge Material Science 
Organisation University of Cambridge
Department Department of Materials Science & Metallurgy
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Cedric Ghevaert - Collaborative project
Collaborator Contribution Collaboration with Sohini Kar-Narayan of the University of Cambridge Department of Materials Science & Metallurgy.
Impact Outputs expected
Start Year 2020
 
Description Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute 
Organisation Babraham Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Cedric Ghevaert - Collaborative project
Collaborator Contribution Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub".
Impact Outputs and outcomes expected 2021
Start Year 2018
 
Description Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute 
Organisation Loughborough University
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Cedric Ghevaert - Collaborative project
Collaborator Contribution Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub".
Impact Outputs and outcomes expected 2021
Start Year 2018
 
Description Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute 
Organisation University of Sheffield
Department Department of Biomedical Science
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Cedric Ghevaert - Collaborative project
Collaborator Contribution Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub".
Impact Outputs and outcomes expected 2021
Start Year 2018
 
Description Computational analyses of spatial transcriptomic data and collaboration on limb development manuscript. 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Computational analyses of spatial transcriptomic data and collaboration on limb development manuscript.
Collaborator Contribution Computational analyses of spatial transcriptomic data and collaboration on limb development manuscript.
Impact Our group has recently started collaborating with Sarah Teichmann's laboratory at the Sanger Institute to obtain help for computational analyses of our recently acquired spatial Transcriptomics data. This collaboration is multi-disciplinary (bioinformatics and regenerative biology). During this process, I have given intellectual input on a paper that the Teichmann group had been assembling that is now in the process of being submitted.
Start Year 2021
 
Description Elisa Laurenti - Max Planck Institute of Immunobiology and Epigenetics 
Organisation Max Planck Society
Department Max Planck Institute of Immunobiology and Epigenetics
Country Germany 
Sector Academic/University 
PI Contribution CSCI PI Elisa Laurenti - Collaborative project
Collaborator Contribution Collaboration with Nina Cabezas-Wallscheid entitled "Molecular regulation of human haematopoietic stem cell quiescence."
Impact Outputs expected 2021
Start Year 2020
 
Description George Vassiliou - Cambridge MRC Cancer Unit 
Organisation University of Cambridge
Department MRC Cancer Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI George Vassiliou - Collaborative project
Collaborator Contribution Collaboration with Christian Frezza of the University of Cambridge's MRC Cancer Unit entitled "Investigation of metabolic vulnerabilities of clonal haematopoiesis clones."
Impact Outputs and outcomes expected 2021
Start Year 2019
 
Description Joint MRC-Japan Agency for Medical Research and Development (AMED) with Bertie Gottgens, also involving University of York 
Organisation University of Tokyo
Country Japan 
Sector Academic/University 
PI Contribution Joint MRC-Japan Agency for Medical Research and Development (AMED) with Bertie Gottgens, also involving University of York
Collaborator Contribution Joint MRC-Japan Agency for Medical Research and Development (AMED) with Bertie Gottgens, also involving University of York
Impact Joint MRC-Japan Agency for Medical Research and Development (AMED) with Bertie Gottgens, also involving University of York
Start Year 2021
 
Description Joint MRC-Japan Agency for Medical Research and Development (AMED) with Elisa Laurenti and Simon Mendez Ferrer, also involving Keio University 
Organisation University of Kumamoto
Country Japan 
Sector Academic/University 
PI Contribution Joint MRC-Japan Agency for Medical Research and Development (AMED) with Elisa Laurenti and Simon Mendez Ferrer, also involving Keio University
Collaborator Contribution Joint MRC-Japan Agency for Medical Research and Development (AMED) with Elisa Laurenti and Simon Mendez Ferrer, also involving Keio University
Impact Joint MRC-Japan Agency for Medical Research and Development (AMED) with Elisa Laurenti and Simon Mendez Ferrer, also involving Keio University
Start Year 2021
 
Description Joo-Hyeon Lee - University of Cambridge, Department of Biochemistry 
Organisation University of Cambridge
Department Department of Biochemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Joo-Hyeon Lee - Collaborative project
Collaborator Contribution Collaboration with Kathryn Lilley of University of Cambridge's Department of Biochemistry.
Impact Outcomes expected 2021
Start Year 2020
 
Description Joo-Hyeon Lee - University of Cambridge, Department of Surgery 
Organisation University of Cambridge
Department Department of Surgery
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Joo-Hyeon Lee - Collaborative project
Collaborator Contribution Lee lab collaborates with Dr Kourosh Saeb-Parsy's group for receiving human lung tissue samples to develop patient-derived human lung organoid models.
Impact Outputs expected 2021
Start Year 2020
 
Description Ludovic Vallier - Abcam 
Organisation Abcam
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI Ludovic Vallier - Collaborative project
Collaborator Contribution Collaboration with Anne Wiblin of Abcam related to anitbodies validations.
Impact Outputs and outcomes expected to begin in 2021
Start Year 2020
 
Description Ludovic Vallier - Bit.bio 
Organisation Bit.Bio
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI Ludovic Vallier - Collaborative project
Collaborator Contribution Collaboration with Mark Kotter of Bit.bio related to research in forward programming.
Impact Outputs and outcomes expected to begin in 2021
Start Year 2020
 
Description Ludovic Vallier - California Institute of Technology 
Organisation California Institute of Technology
Department Division of Biology and Biological Engineering (BBE)
Country United States 
Sector Academic/University 
PI Contribution CSCI PI Ludovic Vallier - Collaborative project
Collaborator Contribution Collaboration with Magdalena Zernicka-Goetz of Caltech's Division of Biology and Biological Engineering.
Impact Outputs and outcomes expected beginning in 2021
Start Year 2020
 
Description Ludovic Vallier - University of California at Davis 
Organisation University of California, Davis
Department UC Davis College of Biological Sciences
Country United States 
Sector Academic/University 
PI Contribution CSCI PI Ludovic Vallier - Collaborative project
Collaborator Contribution Collaboration with Gerald Quon of UC-Davis College of Biological Sciences
Impact Outputs and outcomes expected beginning 2021
Start Year 2020
 
Description Ludovic Vallier - University of Oxford 
Organisation University of Oxford
Department Department of Physiology, Anatomy and Genetics
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Ludovic Vallier - Collaborative project
Collaborator Contribution Collaboration with Shankar Srinivas of Oxford's Department of Physiology, Anatomy and Genetics.
Impact Outputs and outcomes beginning in 2021
Start Year 2020
 
Description Ludovic Vallier - University of Washington 
Organisation University of Washington
Country United States 
Sector Academic/University 
PI Contribution CSCI PI Ludovic Vallier - Collaborative project
Collaborator Contribution Collaboration with Kelly Stevens of the University of Washington's College of Engineering
Impact Outputs and outcomes beginning in 2021
Start Year 2020
 
Description Roger Barker - Lund University 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution CSCI PI Roger Barker - Collaborative Project
Collaborator Contribution Collaboration with Johan Jakobsson titled "Role of transposons in driving inflammation in Parkinson's Disease".
Impact Outputs expected
Start Year 2020
 
Description Roger Barker - Novo Nordisk - Cambridge Design Partnership 
Organisation Cambridge Design Partnership
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI Roger Barker - Collaborative project
Collaborator Contribution Collaboration between Roger Barker, Novo Nordisk and the Cambridge Design Partnership to develop dopaminergic stem cells for the treatment of Parkinson's Disease.
Impact Outputs and outcomes beginning in 2021.
Start Year 2020
 
Description Roger Barker - Novo Nordisk - Cambridge Design Partnership 
Organisation Novo Nordisk
Country Denmark 
Sector Private 
PI Contribution CSCI PI Roger Barker - Collaborative project
Collaborator Contribution Collaboration between Roger Barker, Novo Nordisk and the Cambridge Design Partnership to develop dopaminergic stem cells for the treatment of Parkinson's Disease.
Impact Outputs and outcomes beginning in 2021.
Start Year 2020
 
Description Sanjay Sinha - AstraZeneca 
Organisation AstraZeneca
Department AstraZeneca Sweden
Country Sweden 
Sector Private 
PI Contribution CSCI PI Sanjay Sinha - Collaborative project
Collaborator Contribution Collaborative research with Ryan Hicks of AstraZeneca Sweden.
Impact Outputs and outcomes beginning in 2021
Start Year 2020
 
Description Sanjay Sinha - Imperial College London 
Organisation Imperial College London
Department Department of Bioengineering
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI Sanjay Sinha - Joint Grant awarded by Kusuma Trust
Collaborator Contribution The Kusuma Trust awarded a grant to Dr Sanjay Sinha (Wellcome - MRC Cambridge Stem Cell Institute) and Prof Molly Stevens (Imperial College London) to work together on developing an innovative material strategy to heal the heart. This follows on from some initial successful research carried out by the Stevens Group to develop cardiac patches. This next phase of research will use the expertise of both groups in cardiac cell biology and biomaterials to develop pioneering new materials. If successful, this therapeutic approach will strengthen and support heart regeneration and is potentially a highly promising solution for the treatment of heart failure. We look forward to seeing the outcome of this research and the impact that it could have.
Impact Outcomes expected beginning 2021
Start Year 2020
 
Title A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies - Brian Huntly 
Description This is an open-label repeat dose, multicenter, 2-part study to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily (QD) orally. Part 1 of the study is a dose escalation phase to select the recommended Part 2 dose (RP2D) based on the safety, PK, and PD profiles observed after oral administration of GSK525762. Eligible subjects with select relapsed refractory hematological malignancies (acute myeloid leukemia [AML], non-Hodgkin's Lymphoma [NHL]and multiple myeloma [MM]), will be enrolled in the QD and/or BID dosing cohorts until a MTD is established. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent. . Upon determination of the MTD, twice daily (BID) dosing cohorts may be opened to collect additional safety data and evaluate the preliminary efficacy of GSK525762 administered BID. Part 2 will explore clinical activity at the MTD or RP2D; separate expansion cohorts will be planned for acute myeloid leukemia (AML), non-Hodgkin's Lymphoma (NHL, including an exploratory sub-cohort of subjects with myc and B-Cell Leukemia (BCL)2 and/or BCL6 rearrangements/overexpression [double- and triple-hit lymphoma]), and multiple myeloma (MM). This is the first study of this agent to be conducted in subjects with these relapsed and/or refractory hematological malignancies for which no standard therapies are anticipated to result in a durable remission. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2020
Development Status Under active development/distribution
Clinical Trial? Yes
Impact The results of this study are still being evaluated, but this is the first study of this agent to be conducted in subjects with these relapsed and/or refractory hematological malignancies for which no standard therapies are anticipated to result in a durable remission. 
URL https://clinicaltrials.gov/show/NCT01943851
 
Title A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) - Roger Barker 
Description This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether neflamapimod can reverse hippocampal dysfunction in patients with early-stage HD, as assessed by the virtual water-maze-test for evaluating spatial learning and selected tests on the Cambridge Neuropsychological Test Automated Battery (CANTAB). 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2020
Development Status On hold
Clinical Trial? Yes
Impact The results of this clinical trial are still being assessed. 
 
Title A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease - Roger Barker 
Description This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in patients with manifest Huntington's disease (HD). 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2020
Development Status Under active development/distribution
Clinical Trial? Yes
Impact This clinical trial is ongoing, so its impacts are yet to be assessed. 
 
Title A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial 
Description A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial 
Type Therapeutic Intervention - Cellular and gene therapies
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2019
Development Status Closed
Clinical Trial? Yes
Impact The primary objective is to establish the safety and tolerability of bexarotene in the treatment of relapsing remitting multiple sclerosis. 
 
Title ADIPOA-2 Clinical Trial - Andrew McCaskie 
Description Osteoarthritis (OA) is an incurable and debilitating disease. It has been identified as the world's eleventh highest contributor to disability and affects over 70 million Europeans. There is currently no treatment to prevent progression of the disease. In the absence of effective pharmacological, biological or surgical treatment options, cellular therapies using mesenchymal stem/stromal cells (MSCs) have emerged as potential treatments for this condition. Autologous adipose-derived mesenchymal stromal cells (ASCs) are an attractive option for these cellular therapies because of the abundance of tissue, high frequency of MSCs, and minimally invasive harvest procedure. The EU consortium ADIPOA has shown in a 'first in man' 2-centre Phase I safety study that intraarticular injection of a single dose of autologous ASCs to the knee (18 patients, 12 month follow-up) was well-tolerated, had no adverse effects, and resulted in an improvement in pain score and functional outcome. ADIPOA-2 will build on the work of ADIPOA to deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration. ADIPOA-2 will carry out a multi-centre, randomized clinical trial comparing the use of culture-expanded, autologous adult ASCs in subjects with knee OA with injected Hyaluronan (another widely used therapeutic approach for knee degeneration). This study will involve two major elements: the production of consistent batches of high-quality autologous ASCs under GMP-compliant conditions and the delivery of these cell doses to patients in a trial which will meet all national and European regulatory and ethical standards and which will provide a definitive demonstration of the safety and efficacy of ASCs as a therapy for osteoarthritis. 
Type Therapeutic Intervention - Cellular and gene therapies
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2021
Development Status Actively seeking support
Clinical Trial? Yes
Impact ADIPOA-2 will build on the work of ADIPOA to deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration. 
URL https://adipoa2.eu/
 
Title An Open Label Study to Assess the Safety and Efficacy of Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue in Patients with Parkinson's disease 
Description The Transeuro Transplant study is a trial which will involve grafting foetal tissue into the brain of patients with Parkinson's disease, who are already been followed in the observational study. The tissue inserted in the brain is to help replace and rebuild lost dopamine from the brain due to Parkinson's disease. Only 20 patients will be selected for the transplant. 
Type Therapeutic Intervention - Cellular and gene therapies
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2015
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Clinical trials of cell therapy in PD patients were first performed in Lund in the late 1980s, followed by a number of similar, small trials in other European and North American centres. These initial studies performed on small groups of advanced PD patients were all open label but firmly established safety of the procedure. The results obtained in these trials have shown that the grafted dopaminergic [DA] neurons can survive and function long-term, over more than 10 years, and that some patients have shown clear clinical benefits, especially with respect to their bradykinesia and rigidity, with reductions in L-dopa requirements. Using functional imaging it has also been shown that the grafted DA neurons can restore striatal DA release and provide a sustained re-activation of motor cortical areas, i.e. key areas that were underactive prior to grafting. Post-mortem studies have shown excellent long-term survival of the grafted DA neurons, notwithstanding the observation that some of the long-term surviving transplants (at 12-15 years after grafting) have now been shown to contain signs of PD-related pathologies, i.e. neuronal Lewy-bodies and alpha-synuclein positive inclusions in the grafts. However, such changes have been observed only in some and not in all patients and when seen the extent of the pathology is limited to a small number of the grafted DA cells and the clinical consequence, if any, not known. However, the outcomes of two NIH sponsored double blind placebo controlled trials, which published their main findings in 2001 and 2003, have raised major concerns. In both these trials the grafted patients did not show any significant improvement overall compared to sham-operated controls at 1 and 2 years post grafting. Furthermore, a significant number of patients in both trials developed GIDs, which in some cases were so severe that further neurosurgery was needed to remedy the situation. The reasons for the variable, and overall poor, outcome in these trials, including the generation of GIDs, have been the subject of much debate but have recently centred on three key elements, with an additional possible fourth element: The selection of patients in terms of clinical phenotype, disease stage and pattern of striatal dopaminergic denervation at the time of grafting; The differences in immunosuppressive regimes and the risk that incomplete immunosuppression in combination with the use of solid graft methods may lead to the development of detrimental immune/inflammatory reactions at the graft site with compromise of the grafted dopamine cell function; The mode of engraftment and differences in graft cell survival, and the risk for inhomogeneous delivery of dopaminergic neurons and the generation of potentially dyskinesia-inducing "patchy" innervations in the host striatum; A final possible element is the composition of the grafted tissue and the ratio of serotoninergic to dopaminergic neurons within the graft. There is emerging evidence that serotoninergic neurons can release dopamine in a relatively unregulated fashion given they lack transporters for it, and as such may use L-dopa as a false transmitter which may not only underlie the development of L-dopa induced dyskinesia's but may also contribute to GIDs. Failure of the NIH trials to demonstrate any overall clinical benefits in the grafted patients, and the unexpected and worrisome development of GIDs in a significant number of patients in these trials has represented a major hurdle for the future development of cell based therapies for PD and it is in this and related areas that this project seeks to move the field forward and go beyond the current state of the art for this treatment approach. This project has gathered together all the available expertise in this area to resolve or reduce the risk of the previous complications seen with VM transplants in patients with PD. We will conduct a new round of clinical trials, involving a step-by-step optimisation of all technical aspects of the grafting procedure and patient selection and assessment, in order to improve clinical efficiency and consistency, in the absence of troublesome dyskinesia's. 
 
Title An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies - Roger Barker 
Description Entry into the study should occur at the time the participant completes participation in one of the preceding studies. Upon completion of the inclusion visit, eligible participants will receive either RO7234292 (RG6042) every 8 weeks (Q8W) or RO7234292 (RG6042) every 16 weeks (Q16W) by bolus intrathecal injection. Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W. Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2020
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Clinical trial has not yet been completed. 
 
Title CABL001A2302: A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors 
Description The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs). Patients for this study will be identified based on warning criteria and resistance definition following European Leukemia Network (ELN) 2020 recommendations. In addition, the study will investigate the use of two different posologies. For this, patients will receive asciminib 40 mg (twice-daily) BID or of 80 mg (once daily) once daily (QD). 
Type Therapeutic Intervention - Drug
Year Development Stage Completed 2021
Development Status Under active development/distribution
Clinical Trial? Yes
Impact The trial has only just started and recruitment has not begun at all sites but it offers the prospect of improved treatment for a disease in chronic myeloid leukaemia that can have a significant impact on quality of life and one which, as it disproportionately affects older people, will become increasing prevalent with the ageing of the population. 
 
Title DLBCL Interim Response Evaluation for Customised Therapy (DIRECT) - Dan Hodson 
Description The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy. Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor. Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable. Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Initial development
Year Development Stage Completed 2021
Development Status Under active development/distribution
Clinical Trial? Yes
Impact It is too early to describe the impacts of this clinical trial, but the trial seeks to improve diagnostic measures related to high-grade B cell lymphoma. 
URL https://clinicaltrials.gov/ct2/show/NCT04226937?term=NCT04226937&draw=2&rank=1
 
Title Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease - Roger Barker 
Description The study is designed to assess the long term tolerability of ProSavin and whether it is safe and efficacious in patients administered ProSavin from the PS1/001/07 study. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2020
Development Status Under active development/distribution
Clinical Trial? Yes
Impact The results of this clinical trial are still under assessment. 
 
Title RESTORE: Recovery and Survival of Stem Cell Originated Red Cells - Cedric Ghevaert/NHS Blood and Transplant 
Description A single centre randomised, controlled phase I cross-over trial in healthy volunteers to assess the recovery and survival of a mini-dose of red blood cells derived from CD34+cells isolated from adult blood vs standard donated red blood cells. Randomised, single blind, cross-over design to compare the recovery and survival of red blood cells manufactured from CD34+ cells isolated from adult blood compared with standard donated red blood cells. The order in which each recipient receives the standard or manufactured red blood cells is randomised and recipients will be blinded to that order. 
Type Therapeutic Intervention - Cellular and gene therapies
Current Stage Of Development Initial development
Year Development Stage Completed 2021
Development Status Under active development/distribution
Clinical Trial? Yes
Impact There are a small number of patients with rare blood group types for whom NHS Blood and Transplant cannot meet the transfusion requirements. New red blood cells can be grown from human blood stem cells in the laboratory. We hope that this will provide us with a novel transfusion product for these patients in the future, some of whom require regular transfusions throughout life (e.g. for thalassemia or sickle cell disease). 
URL https://www.nhsbt.nhs.uk/clinical-trials-unit/current-trials-and-studies/restore/
 
Title Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease (SUNRISE-PD) - Roger Barker 
Description This study consists of two parts. Part A is an open-label dose-escalation phase in which participants are enrolled in cohorts and will receive one of approximately three escalating doses of OXB-102 (AXO-Lenti-PD). Part B is a randomized, double-blind phase in which participants will be randomized to either an active group receiving the selected dose from Part A, or to a control group receiving an imitation surgical procedure (ISP). 
Type Therapeutic Intervention - Cellular and gene therapies
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2020
Development Status Under active development/distribution
Clinical Trial? Yes
Impact This clinical trial is ongoing, and its potential impacts have not yet been assessed. 
URL https://clinicaltrials.gov/show/NCT03720418
 
Title TAMARIN: Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms - Simon Mendez-Ferrer 
Description Myeloproliferative neoplasms (MPNs) are blood cancers which affect the normal production of blood cells from the bone marrow. They are caused by changes (mutations) in blood stem cells, frequently in the genes that produce proteins called JAK2, CALR or MPL. MPNs have a risk of developing to an acute leukaemia (a more advanced stage of disease) and currently has no effective cure, apart from bone marrow transplantation which is not possible for many patients. Recent work in mouse studies has suggested that tamoxifen, a drug widely used to treatment breast cancer, may reduce the number of mutated cells by mimicking oestrogen (a female sex hormone) which has a role in the survival and production of new stem cells that give rise to blood cancers. In these studies, tamoxifen prevented the excessive production of blood cells by restoring normal levels of cell death in the mutated cells. This is a single arm, multicentre phase II trial designed to assess if adding tamoxifen to patients receiving therapy for their MPN reduces the number of mutated cells found in the blood by = 50% after 24 weeks of treatment compared to the start of the study. Collection of blood and bone marrow samples will also allow laboratory researchers to study the biological effects of tamoxifen and how this correlates with the patient's disease and response to therapy. Patients will receive treatment with 20mg once daily (oral tablet) of tamoxifen with their normal therapy for their MPN. 42 patients will be recruited from 13-15 UK centres over 12 months. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2020
Development Status Actively seeking support
Clinical Trial? Yes
Impact The results of this clinical trial are still being evaluated and should be published in the near future. 
URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005497-38
 
Company Name STROMA BIOSCIENCES LIMITED 
Description A company whose goal is discovering novel stroma-intrinsic targets and therapeutics specifically targeting these mechanisms in a broad range of diseases. 
Year Established 2020 
Impact A company whose goal is discovering novel stroma-intrinsic targets and therapeutics specifically targeting these mechanisms in a broad range of diseases.
 
Company Name HEPATOTARGET THERAPEUTICS LTD. 
Description A company working in biotechnology through the Babraham Research Campus at the University of Cambridge. 
Year Established 2019 
Impact A company working in biotechnology through the Babraham Research Campus at the University of Cambridge.
 
Company Name CELLADVICE LTD 
Description Consultancy for companies involved in transfusion products or cell therapies. 
Year Established 2019 
Impact This consultancy advises companies and practitioners in relation to transfusion products and cell therapies.
 
Company Name ALVEO THERAPEUTICS LTD 
Description In process of raising funds. will be focused on cancer early detection assays 
Year Established 2021 
Impact In process of raising funds. will be focused on cancer early detection assays
 
Company Name ACULIVE THERAPEUTICS LIMITED 
Description Newly form company 
Year Established 2021 
Impact Newly form company
 
Company Name XAP THERAPEUTICS LIMITED 
Description Start up to produce platelet-like particles in vitro 
Year Established 2017 
Impact Start up to produce platelet-like particles in vitro
 
Company Name TROPOFOUR THERAPEUTICS LIMITED 
Description This company is developing compounds to control platelet formation. 
Year Established 2019 
Impact The company possesses potentials to impact clinical therapies and research paradigms.
 
Description Article published in The Sun about Sinha's Lab work on regenerating heart tissue 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Article published in The Sun about Sinha's Lab work on regenerating heart tissue
Year(s) Of Engagement Activity 2022
URL https://www.thesun.co.uk/health/17636231/hearts-self-heal-regenerative-medicine/
 
Description BBC News story related to the Nature Communications publication: Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors. 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact BBC News story related to the Nature Communications publication: Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors. Nature Communications. https://doi.org/10.17863/CAM.64705
Year(s) Of Engagement Activity 2021
URL https://www.stemcells.cam.ac.uk/news/changes-detected-brca1-breast-cells-cancerous
 
Description BBC news story related to the Nature Publication the Transcriptional changes in the mammary gland during lactation revealed by single cell sequencing of cells from human milk 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact BBC news story related to the Nature Publication the Transcriptional changes in the mammary gland during lactation revealed by single cell sequencing of cells from human milk
Year(s) Of Engagement Activity 2022
URL https://www.stemcells.cam.ac.uk/news/live-cells-discovered-human-breast-milk-could-aid-breast-cancer...
 
Description Blog Post for Nature Portfolio Cancer Community's 'Behind the Paper' Blog Series - Elisa Laurenti 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Nature Portfolios online 'Cancer Community' provides a forum where researchers, professional practitioners and other interested parties may discuss current and past research into a variety of scientific topics. The community's 'Behind the Paper' blog series gives researchers who publish their findings in Nature journals an opportunity to describe and discuss their publication and working processes.
Year(s) Of Engagement Activity 2020
URL https://cancercommunity.nature.com/posts/a-transcriptomic-continuum-of-differentiation-arrest-identi...
 
Description Bluesci podcast: Lab grown organoids and regenerative medicine - Fotis Sampaziotis 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Undergraduate students
Results and Impact Podcast with student-run science journalism group Blusci on current research.
Year(s) Of Engagement Activity 2021
 
Description CBC on Virtual Tour: Cambridge Children's - David Rowitch 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact Online presentation livestreamed online and bookable by the public organised by Cambridge Biomedical Campus to share updates about and host Q&A on the Cambridge Childrens project.
Year(s) Of Engagement Activity 2021
 
Description Cambridge Festival HeLa book club - Emily Calderbank 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Attendance at a book club session arranged by the University of Cambridge and Gurdon Institute PE teams, to discuss Rebecca Skloot's "The Immortal Life of Henrietta Lacks" as part of the Cambridge Festival.
Year(s) Of Engagement Activity 2021
URL http://www.henriettacamfest.co.uk/book-club-resources
 
Description Code for a Change website - Mariana Quiroga-Londono 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Online platform with coding challenges in Python to help build skills and challenge users to complete bioinformatics challenges.
Year(s) Of Engagement Activity 2021,2022
URL http://www.codeforachange.com
 
Description Conference Organiser/Chair - Neuromatch 3.0 Conference, Theme B: Neural Excitability, Synapses, and Glia - Thora Karadottir 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Based on the successful mind-matching session at the Cognitive Computational Neuroscience (CCN) conference and previous Neuromatch conference with more than 6k attendees, organisers decided to create an online unconference for all neuroscientists. Organisers built a better online experience for neuroscience conferences by making them more open, inclusive, and democratic. Thora was a co-organiser for one of the conference's research themes.
Year(s) Of Engagement Activity 2020
URL https://neuromatch.io/
 
Description Cord blood discussion sessions (PE Seed Fund) - Emily Calderbank 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact Focus group sessions with potential, expectant or current mothers to discuss the uses of donated umbilical cord blood in research and inform conversations with research nurses and healthcare professionals about common questions, concerns or misconceptions donors may have.
Year(s) Of Engagement Activity 2021
 
Description Cystic Fibrosis Trust online focus group - Laetitia Pinte; Marta Vila Gonzalez 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Third sector organisations
Results and Impact Zoom focus group with representatives from patient networks and staff teams at the Cystic Fibrosis Trust staff to discuss current research at CSCI and ways of engaging and involving CF patients in future.
Year(s) Of Engagement Activity 2021
 
Description Digital Student Outreach during Coronavirus School Closures - Jamie McGinn 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Schools
Results and Impact The Medical Research Zone was a themed zone that ran in the summer term of 2020 as part of I'm a Scientist, Stay at home. The activity helped students stay connected with STEM during the coronavirus closures.
Year(s) Of Engagement Activity 2020
URL https://medical20.imascientist.org.uk/profile/jamiemcginn/
 
Description Digital Student Outreach during Coronavirus School Closures - Robyn Macrae 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Schools
Results and Impact The Medical Research Zone was a themed zone that ran in the summer term of 2020 as part of I'm a Scientist, Stay at home. The activity helped students stay connected with STEM during the coronavirus closures.
Year(s) Of Engagement Activity 2020
URL https://medical20.imascientist.org.uk/profile/robynmacrae/
 
Description Digital Student Outreach during Coronavirus School Closures - Shaline Fazal 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Schools
Results and Impact The Medical Research Zone was a themed zone that ran in the summer term of 2020 as part of I'm a Scientist, Stay at home. The activity helped students stay connected with STEM during the coronavirus closures.
Year(s) Of Engagement Activity 2020
URL https://medical20.imascientist.org.uk/profile/shalinefazal/
 
Description Edinburgh Parkinson's lecture - Roger Barker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Online invited lecture through Zoom to provide a research update for members of the Parkinson's UK community.
Year(s) Of Engagement Activity 2021
 
Description Instagram 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Launch of new Instagram account for the Institute at @SCICambridge, primarily as a channel to r(a) each community or special interest groups and (b) younger students and early career researchers .
Year(s) Of Engagement Activity 2021,2022
URL http://www.instagram.com/scicambridge
 
Description Interview for 'Pager' Podcast (s2e2) - Sanjay Sinha 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Every few weeks, listeners tune in to the 'Pager' podcast to hear about the topics changing the future of biology and medicine. The heart is notoriously bad at regenerating following damage to the myocardium. On the horizon are cell therapies that could restore cardiac function following damage. In this episode, Dr Sanjay Sinha, a British Heart Foundation Senior Research Fellow, and a consultant cardiologist at Addenbrooke's hospital, joins us discuss a stem cell derived cardiac 'patch', which could be transplanted into patients for heart repair after myocardial infarction. The potential of cardiac cells derived from iPSCs for personalised approached to treatment, and for modeling disease, are also discussed.
Year(s) Of Engagement Activity 2020
URL https://www.buzzsprout.com/688397/4794047-regenerating-the-damaged-heart-with-sanjay-sinha
 
Description Interview for 'Pager' Podcast (s2e5) - Roger Barker 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Every few weeks, listeners tune in to the 'Pager' podcast to hear about the topics changing the future of biology and medicine. In this episode, Dr Roger Barker joins us to discuss our current understanding of Parkinson's disease. The first half of the conversation focuses on the disease process. Is Parkinson's a single disease or a group of connected diseases? How might this difference affect our thinking surrounding Parkinson's? The discussion then switches to the development of cell and gene therapies for Parkinson's. The unique challenges of a cell therapy for the brain, as well as the efficacy of a neurotrophic factor 'GDNF', are both discussed. Dr Barker is the professor of clinical neuroscience at the University of Cambridge, and a consultant neurologist at Addenbrooke's hospital in Cambridge. His lab at the John van Geest Centre for Brain Repair is focused on better understanding both Parkinson's and Huntington's disease, as well as on developing therapies to treat these diseases.
Year(s) Of Engagement Activity 2020
URL https://www.buzzsprout.com/688397/5141326-parkinson-s-disease-in-2020-with-roger-barker
 
Description Interview for 'StemCells@Lunch Digested' Podcast (e101) - Jose Silva 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact StemCells@Lunch Digested is a podcast that keeps the public up to date with current research taking place in the stem cell research community. Listeners can hear guest speakers discuss their work, how they got to where they are today and their hopes for the future of stem cell research. The podcast is hosted by King's College London Centre for Stem Cells & Regenerative Medicine. PhD student Christopher Lambert interviews Dr José Silva, a group leader at the Welcome-MRC Cambridge Stem Cell Institute. Dr Silva tells us about his career path from PhD to group leader and his current research in cellular reprogramming. They discuss the importance of collaboration in basic research and the need for a long-term, step-wise approach to progress the field of cellular reprogramming. Dr Silva also looks to the future, talking about his move into creating synthetic embryos.
Year(s) Of Engagement Activity 2020
URL https://soundcloud.com/user-563815853/episode-101-dr-jose-silva-it-is-the-basic-research-that-leads-...
 
Description Interview for 'StemCells@Lunch Digested' Podcast (e107) - Ludovic Vallier 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact StemCells@Lunch Digested is a podcast that keeps the public up to date with current research taking place in the stem cell research community. Listeners can hear guest speakers discuss their work, how they got to where they are today and their hopes for the future of stem cell research. The podcast is hosted by King's College London Centre for Stem Cells & Regenerative Medicine. Professor Ludovic Vallier, Professor of Regenerative Medicine within the Department of Surgery at Cambridge University and director of the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre hIPSCs (human induced pluripotent stem cells) core facility, is interviewed by PhD student Alice Vickers. He talks about his work using human pluripotent cells to generate pancreas, lung, gut and liver cells. He speaks about how his involvement in industry aims to generate cell types for clinical studies and for cell based therapy.
Year(s) Of Engagement Activity 2020
URL https://soundcloud.com/user-563815853/episode-107-prof-ludovic-vallier-the-drive-is-to-generate-more...
 
Description Interview for 'StemCells@Lunch Digested' Podcast (e97) - Simon Mendez-Ferrer 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact StemCells@Lunch Digested is a podcast that keeps the public up to date with current research taking place in the stem cell research community. Listeners can hear guest speakers discuss their work, how they got to where they are today and their hopes for the future of stem cell research. The podcast is hosted by King's College London Centre for Stem Cells & Regenerative Medicine. PhD Student Dr Beibei Du speaks with Dr Simón Méndez-Ferrer, a Reader in Transfusion Medicine at the University of Cambridge. They discuss what controls blood stem cell behaviour, including whether you are awake or asleep. Simón also talks about how understanding what makes blood stem cells move can be used in stem cell transplants to treat blood cancers.
Year(s) Of Engagement Activity 2020
URL https://soundcloud.com/user-563815853/episode-97-dr-simon-mendez-ferrer-how-can-targeting-where-stem...
 
Description Interview for 'The Academinist' Podcast (e4) - Oluwaseun Ogundele 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The podcast about equality and feminism in STEM. Join Rebecca & Jodi - two neuroscientists based in London - as they discuss with guests how inequality affects womxn and minorities in STEM*, and ponder what we can all do to fix this as feminists in science. Also, we are joined by Stem Cell Research Assistant and Science Activist Oluwaseun Ogundele.
Year(s) Of Engagement Activity 2020
URL https://podcasts.apple.com/gb/podcast/being-visible-with-oluwaseun-ogundele/id1513830838?i=100048941...
 
Description Interview for 'The Stem Cell Podcast' (e177) - Ludovic Vallier 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The Stem Cell Podcast was launched in 2013 by two research scientists, Drs Yosif Ganat and Chris Fasano. Their goal was to create an accessible, entertaining resource for scientists to keep current on the latest developments in stem cell research, as well as to interview key influencers in the stem cell field about their work and perspectives on the field. Dr. Ludovic Vallier is a Professor of Regenerative Medicine at the Cambridge Stem Cell Institute and Director of the NIHR Cambridge Biomedical Centre hiPSC core facility. His lab studies the basic mechanisms controlling the differentiation of pluripotent cells into endoderm progenitors from which the pancreas, lung, gut and liver originate. He discussed his research and the current state of stem cell biology within this podcast episode.
Year(s) Of Engagement Activity 2020
URL https://stemcellpodcast.com/ep-177-molecular-mechanisms-of-differentiation-featuring-dr-ludovic-vall...
 
Description Interview for 'Your Digital Mentor' Podcast (s1e5) - Oluwaseun Ogundele 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact 'Your digital mentor' podcast is a series that aims to provide access to conversations around mentoring and other aspects of research and career development, with a focus on LMICs. Episode Summary: Short description: We discuss what imposter syndrome is and how to get out of your own way. Guests: Daniela Robles and Oluwaseun Ogundele. Prologue: Isabela Malta. Episode description: Imposter syndrome is a psychological phenomenon when a person feels they are a fraud or don't deserve their achievements and that you achieved them solely through luck. This phenomenon disproportionately affects women and people of colour, but anyone can succumb to it. It happens when someone cannot internalise their own success. In this episode we discuss these internal narratives and how to overcome them and 'reach for the stars'!
Year(s) Of Engagement Activity 2020
URL https://your-digital-mentor.simplecast.com/episodes/imposter-syndrome-pS61bOE5
 
Description Interview for European Pharmaceutical Review - Roger Barker 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Dr Roger Barker, University of Cambridge, UK and Eric Anthony, International Society for Stem Cell Research (ISSCR), describe how stem cells are regulated around the world and why this is important for patient safety.
Year(s) Of Engagement Activity 2020
URL https://www.europeanpharmaceuticalreview.com/article/117011/stem-cells-in-the-clinic-how-are-they-re...
 
Description Interview for International Society of Hematology's 'Simply Blood' Blog - Elisa Laurenti 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact As members of the International Society of Hematology (ISEH), we place great value in the communication and collaboration occurring between our colleagues around the world. This blog has been established to help continue those interactions beyond the annual meeting and past the purely scientific realm. We hope Simply Blood will act as a lively platform for open discussions about how we function, grow and engage as scientists. This week on Simply Blood we are continuing our 2020 Interview Spotlight Series. In Part II we are featuring the ISEH 2020 New Investigator's Invitee: Elisa Laurenti, MBS; PhD. Dr. Laurenti answers questions about her work, trends in hematology, mentorship, and more.
Year(s) Of Engagement Activity 2020
URL https://www.simplyblood.org/2020/07/2020-interview-spotlight-series-part-ii.html
 
Description Interview for October 2020 Branch Meeting (Parkinson's UK, West Hertfordshire) - Roger Barker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Professor Roger Barker, Head of the Brain Repair Centre in Cambridge, was the special guest of the West Hertfordshire branch of charity Parkinson's UK at its October branch meeting. In a fascinating talk, Prof. Barker took attendees through some of the previous research into dopamine and some exciting new dopamine cell therapies for repairing the brain in Parkinson's. The presentation included outlining which patients may best benefit from such an intervention as well as the very latest news on stem cell transplants for Parkinson's patients in the UK and globally.
Year(s) Of Engagement Activity 2020
URL https://parkinsons-westherts.org.uk/october-meeting-with-professor-roger-barker/
 
Description Interview for Social Media Broadcast (Allen Institute YouTube) - Thora Karadottir 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Allen Distinguished Investigator Ragnhildur Thóra Káradóttir describes how the tools that are available now are helping to support neuroscience, immunology and psychiatric disease research better than ever before.
Year(s) Of Engagement Activity 2020
URL https://www.youtube.com/watch?v=A2IRX46Stus
 
Description Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Adam Young 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film, Dr Adam Young (Franklin Group) describes how he refocused his work using viruses as 'tools' to investigate the interaction between stem cells and immune cells in the brain. Now, his team are exploring similarities between the coronavirus, and the measles, mumps and rubella viruses and their long-standing vaccines. Early results from the team's Covid-19 research are available in a MedRxiv preprint at https://doi.org/10.1101/2020.04.10.20053207v1
Year(s) Of Engagement Activity 2020
URL https://www.youtube.com/watch?v=gamjz_9VL2A
 
Description Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Cedric Ghevaert 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film Dr Cédric Ghevaert introduces his group, who are investigating blood clotting in coronavirus patients. Amie, James, Moyra and Winnie answered our questions about the team's recent work with collaborators at the University of Bristol.
Year(s) Of Engagement Activity 2020
URL https://www.youtube.com/watch?v=DWSLc8lcRzA
 
Description Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Fotios Sampaziotis 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film, Dr Fotios Sampaziotis (Vallier group), shares how he discovered his work on stem-cell derived bile duct 'organoids' could provide a potential mechanism to study virus uptake and screen drugs to fight the pandemic.
Year(s) Of Engagement Activity 2020
URL https://www.youtube.com/watch?v=GUOC2jr9r74
 
Description Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Maria Colzani 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film, we meet Dr Maria Colzani from the Sinha Group. Maria is working with colleagues on a collaborative project to investigate heart tissue damage seen in coronavirus patients.
Year(s) Of Engagement Activity 2020
URL https://www.youtube.com/watch?v=jCYbR3pUrKI
 
Description Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Nicole Mende and Fernando Calero 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film, we hear from members of the Göttgens and Laurenti Groups who are taking part in a collaborative Cambridge project on coronavirus. Dr Fernando Calero and Dr Nicole Mende describe their work using genomic techniques to study Covid-19 patient samples.
Year(s) Of Engagement Activity 2020
URL https://www.youtube.com/watch?v=8-U4Qnb0wk0
 
Description Interview for Social Media Broadcast (Lucy Cavendish College, University of Cambridge YouTube) - Aishwarya Jacob 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Since the first UK COVID-19 lockdown began, Lucy Cavendish College at the University of Cambridge has invited members of its College community to provide information about their lives and research in the form of presentations and blog posts. This fascinating talk details Dr Aishwarya Jacob's career in cancer-related research and Cardiovascular Biology, as well as her future dreams to clone dinosaurs.
Year(s) Of Engagement Activity 2020
URL https://www.lucy.cam.ac.uk/events/wait-why-am-i-here-again-and-how-did-i-get-here-tale-confused-post...
 
Description Interview for Social Media Broadcast (seuninscience YouTube) - Elena Corujo-Simon 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact In this series, Oluwaseun, a (British Nigerian) Science Research Assistant working in Stem Cell Research at the Wellcome-MRC Cambridge Stem Cell Institute, explores the narrative of black girl in science, the reality of the lack of BME representation in a predominantly white working field and her journey and experience in this STEM field. The channel hopes to represent a platform to inspire others like her to keep the hustle and live the dream in reality. She regularly interviews fellow scientists and has discussions about their career progressions, with some emphasis on issues in Academia such as the gender gap, lack of representation in science, being a minority in STEM and so forth.
Year(s) Of Engagement Activity 2020
URL https://www.youtube.com/watch?v=L2kNI5T0uoA
 
Description Interview for Social Media Broadcast (seuninscience YouTube) - Elisa Laurenti 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact In this series, Oluwaseun, a (British Nigerian) Science Research Assistant working in Stem Cell Research at the Wellcome-MRC Cambridge Stem Cell Institute, explores the narrative of black girl in science, the reality of the lack of BME representation in a predominantly white working field and her journey and experience in this STEM field. The channel hopes to represent a platform to inspire others like her to keep the hustle and live the dream in reality. She regularly interviews fellow scientists and has discussions about their career progressions, with some emphasis on issues in Academia such as the gender gap, lack of representation in science, being a minority in STEM and so forth.
Year(s) Of Engagement Activity 2020
URL https://www.youtube.com/watch?v=xM5x3VmDwO4
 
Description Interview for Wall Street Journal's 'The Future of Everything' Podcast (Episode: The Blood of the Future...) - Cedric Ghevaert 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Research into making blood in the lab for use in the clinic is an area the Ghevaert group have been building up expertise over the past decade. However, the recent Covid-19 pandemic has brought greater awareness to the possibilities offered by producing blood in the lab. As the Wall Street journal's article and podcast highlight, during the peak of the pandemic the number of blood donations was greatly reduced and this reduction has led to an increased understanding of the need to look for alternatives to donations to maintain blood supplies. The group have developed a particular expertise in the production of platelets and red cells from human pluripotent stem cells. The team are using and developing methodologies that can produce clinical grade products within the constraints of affordable manufacturing processes. Platelets are the smallest cell in the body and are responsible for key functions such as blood clotting and red cells are essential for carrying oxygen around the body. In the interview, Cédric talks about the group's research and the planned clinical trial RESTORE, which is currently in development. The trial will be the first-in-human clinical trial of red blood cells grown in the laboratory from adult donor blood stem cells and aims to recruit its first patient towards the end of Spring 2021.
Year(s) Of Engagement Activity 2020
URL https://www.stemcells.cam.ac.uk/news/2018the-blood-of-the-future-could-be-made-in-a-lab2019-2013-dr-...
 
Description Invited Speaker - 13th International Symposium on Health Informatics and Bioinformatics - Ana Cvejic 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The International Symposium on Health Informatics and Bioinformatics (HIBIT) is now in its thirteenth year. The symposium aims to bring together academics, researchers and practitioners who work in these popular and fulfilling areas and to create the much-needed synergy among medical, biological and information technology sectors. HIBIT is one of the few conferences emphasizing such synergy. HIBIT provides a forum for discussion, exploration and development of both theoretical and practical aspects of health informatics and bioinformatics and a chance to follow current research in this area by networking with other bioinformaticians.
Year(s) Of Engagement Activity 2020
URL https://hibit2020.sabanciuniv.edu/speakers/
 
Description Invited Speaker - 2020 UK-Japan Neuroscience Symposium - Thora Karadottir 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The third "UK-Japan Neuroscience Symposium" was held in Edinburgh at the John McIntyre Conference Centre on 3-5 February 2020. The meeting was co-sponsored by the Medical Research Council (MRC) and the Japan Agency for Medical Research and Development (AMED). Building on the success of the London 2018 and Chiba 2019 meetings of the two Neuroscience communities, the Edinburgh 2020 meeting aimed to further establish collaborative links and exchange of ideas between the two countries. The Symposium comprised two days of talks (20 minutes plus 5 minutes discussion each) and poster sessions from UK and Japanese Neuroscience scientists. The Symposium covered a wide range of topics including "Advanced imaging methods for understanding brain function", "Strategies and synaptopathy of neurodegenerative conditions", and "Synapse and circuit development in relation to neuropsychiatric conditions".
Thora provided a presentation on Day Two entitled "Oligodendrocyte precursor cells become heterogeneous with age: different functional cell states".
Year(s) Of Engagement Activity 2020
URL https://www.bna.org.uk/mediacentre/events/uk-japan-neuroscience-symposium-2020/
 
Description Invited Speaker - 2nd NCRI AML Academy - Brian Huntly 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Sessions will cover the management of older (and younger) adults with AML, emerging drug and antibody targeted therapies, genomics in diagnosis and management, novel therapeutic strategies in relapsed AML, the David Grimwade memorial lecture and a transplant roundtable (presented cases with panel discussion). In the afternoon, the masterclasses will be based on management of relapsed AML and nursing and the day will end with a debate: DA is still the standard induction therapy for all fit AML patients in the UK.
Year(s) Of Engagement Activity 2020
URL https://www.rcpath.org/event/2nd-ncri-aml-academy.html
 
Description Invited Speaker - 2nd Stem Cells UK Conference - Elisa Laurenti 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This one day meeting aims to bring together stem cell researchers from across the UK to share research ideas, forge collaborations and meet friends old and new. Elisa presented a research paper entitled "Haematopoietic stem and progenitor cell landscapes: location matters".
Year(s) Of Engagement Activity 2020
URL https://www.stemcells.cam.ac.uk/files/stem_cells_uk_23.11.20_programme_final.pdf
 
Description Invited Speaker - 2nd Stem Cells UK Conference - Ludovic Vallier 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This one day meeting aims to bring together stem cell researchers from across the UK to share research ideas, forge collaborations and meet friends old and new. Ludovic presented a research paper entitled "Function of cell cycle in stem cell differentiation".
Year(s) Of Engagement Activity 2020
URL https://www.stemcells.cam.ac.uk/files/stem_cells_uk_23.11.20_programme_final.pdf
 
Description Invited Speaker - Cold Spring Harbor Asia Conference, Frontiers in Single Cell Genomics (Oct 2020) - Bertie Gottgens 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The conference included six oral sessions and one poster session covering the latest findings across many topics in Single Cell. Many talks were selected from the openly submitted abstracts on the basis of scientific merit and relevance. Social events throughout the conference provided ample opportunity for informal interactions.

Major Topics included:
1.Technology development
2. Developmental Biology
3. Cancer Biology
4. Computational biology
5. Single cell epigenomics
6. Single cell transcriptional profiling
7. Single cell DNA analysis
8. Single cell imaging
9. Next-generation sequencing

Bertie served as one of the twenty-four invited speakers.
Year(s) Of Engagement Activity 2020
URL https://www.csh-asia.org/?content/404
 
Description Invited Speaker - Cold Spring Harbor Laboratory, 8th Summer Conference on Glia in Health and Disease Virtual Conference 2020 - Thora Karadottir 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The eighth summer conference on Glia in Health & Disease went fully virtual and began late morning EDT on Thursday, July 16, 2020. It ended late afternoon EDT on Sunday, July 19, 2020. Oral sessions were confined to later morning and afternoon sessions EDT to maximize access by participants from around the world. The proposed meeting assembled the leaders in the field, together with junior faculty, postdoctoral fellows and graduate students, to discuss new, cutting-edge developments in the study of all aspects of glial biology in health and disease. The format of the meeting included a number of virtual oral sessions and a virtual poster session throughout. Each oral session included invited speakers and speakers selected from submitted abstracts. For this reason, abstracts from accomplished junior and senior investigators were warmly invited. Thora served as an invited Co-Chair.
Year(s) Of Engagement Activity 2020
URL https://meetings.cshl.edu/meetings.aspx?meet=GLIA&year=20
 
Description Invited Speaker - Developmental Biology 11th course: From Stem Cells to Morphogenesis - Joo-Hyeon Lee 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact The objective is to expose the students to the recent concepts in Developmental Biology, including highlighting their important contribution to the stem cell field and clinical sciences. Various domains of the Developmental Biology field are addressed, not only across the variety of embryonic models but also across the diversity of approaches (large-scale and translational approaches, mathematical modeling, biophysical approaches).
Year(s) Of Engagement Activity 2020
URL https://training.institut-curie.org/courses/developmental-biology-8
 
Description Invited Speaker - Global K-BioX Seminar - Joo-Hyeon Lee 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presentation entitled "Stem cells and their dynamic niche in lung regeneration".
Year(s) Of Engagement Activity 2020
URL https://kbiox.org/seminar/seminar.php?boardid=kbxseminar&mode=view&idx=4&sk=&sw=&offset=&category=%E...
 
Description Invited Speaker - International Society for Stem Cell Research Digital Meeting on Organoids - Joo-Hyeon Lee 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The International Society for Stem Cell Research (ISSCR) will host a four-part digital meeting series featuring a global line-up of speakers who will discuss their latest organoid research. Applying Organoids: The 3D Frontier, co-sponsored by STEMCELL Technologies, will be moderated by Melissa Little, PhD, Murdoch Children's Research Institute, Australia and Toshiro Sato, PhD of Keio University School of Medicine. Each installment of the meeting series will be 90 minutes and include presentations around emerging research and a question and answer session with all presenting scientists. Part I on 7 October will explore research using adult and pluripotent stem cell-derived organoids to recapitulate and understand human development processes, the development of individual endodermal derivatives as well as their organization into complex functional units, and modeling complex human neuropsychiatric disease. Joo participated in "Part 2: Modeling Development and Disease II".
Year(s) Of Engagement Activity 2020
URL https://www.isscr.org/news-publicationsss/isscr-news-articles/article-listing/2020/10/01/isscr-launc...
 
Description Invited Speaker - London Stem Cell Network/Bio-Techne Organoid Virtual Workshop - Joo-Hyeon Lee 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Bio-Techne is proud to be partnering with the London Stem Cell Network (LSCN) to present our first Stem Cell and Organoid Virtual Workshop. Please join us for this exciting event to learn more from leading experts on the advances in stem cells and organoids to help further your projects. Joo gave a presentation entitled "Inflammatory Niches Direct Lung Regeneration".
Year(s) Of Engagement Activity 2020
URL https://info.bio-techne.com/LSCN-OrganoidVirtualWorkshop_LP-webinar-main.html
 
Description Invited Speaker - MRC Human Genetics Unit Symposium - Ana Cvejic 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Ana was invited to speak at the 2020 MRC Human Genetics Unit Symposium, where she provided a presentation entitled "Investigating human blood development at the single-cell level."
Year(s) Of Engagement Activity 2020
URL https://www.ed.ac.uk/files/atoms/files/aberrant_cell_programme.pdf
 
Description Invited Speaker - MSVirtual2020, 8th Joint ACTRIMS-ECTRIMS Meeting - Robin Franklin 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Robin spoke during the 'European Charcot Foundation Symposium', where he presented a talk entitled 'Potential Targets for Remyelination'.
Year(s) Of Engagement Activity 2020
URL https://msvirtual2020.org/
 
Description Invited Speaker - The 25th Congress of the European Hematology Association, Molecular Haemopoiesis Workshop Symposium - Ana Cvejic 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Ana was invited to speak at a workshop for the 25th Congress of the European Hematology Association. Information about the virtual conference is as follows: The world has changed tremendously, due to the impact of COVID-19 and for the first time in its history, EHA organized the Annual Congress in a full virtual edition: EHA25 Virtual. Not only was the 25th EHA Congress a success, it also reached a ground-breaking record of nearly 27,000 registrations. Participants were able to access latest hematology and sub-specialty news, unpublished clinical and translational research results, and new evidence-based approaches to diagnosis and treatment. A wealth of scientific and educational content was shared, including special thematic sessions focused on topics such as: Acute leukemia, Chronic lymphoid neoplasms, Chronic myeloid neoplasms, Coagulation disorders, Immunology, Lymphoma, and Red and white cell disorders.
Year(s) Of Engagement Activity 2020
URL https://library.ehaweb.org/eha/#!*menu=6*browseby=3*sortby=2*ce_id=1766*featured=16775
 
Description Invited Speaker - The 82nd Annual Meeting of the Japanese Society of Hematology - Bertie Gottgens 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The main theme of this congress was "Exploring diversity of Hematology." In the field of Hematology, basic science and clinical issues are strongly connected. New technology for medicine is applied soon after invented, and important scientific subjects have been found from patients with hematological diseases, proving the importance of "Bed to Bench, and Bench to Bed." For the future development of the field of Hematology, it is very important to involve diverse researchers in basic and clinical fields. Young doctors, senior doctors, those in basic and clinical fields, working in hospitals, academic institutions, and companies, are all welcome to the congress. Bertie acted as an invited speaker during a symposium entitled 'Evolving paradigm for blood cell differentiation'.
Year(s) Of Engagement Activity 2020
URL http://www.jshem.or.jp/82/en/index.html
 
Description Invited Speaker - University of Oslo Institute of Basic Medical Sciences Nansen Neuroscience Lecture 2020 - Thora Karadottir 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The Nansen Neuroscience Lectures (NNL) honour Nansen's ground-breaking contribution to neuroscience, and since 10.10.10 the event is part of the Norwegian Academy of Science and Letters annual Nansen-celebration. Keeping the brain in shape is a prerequisite for good life, and particularly at old age, when age-associated diseases encroach upon us. Here we get updated on the current advances. Thora presented an invited lecture entitled "Myelin plasticity - a mechanism of learning and brain repair".
Year(s) Of Engagement Activity 2020
URL https://www.med.uio.no/imb/english/research/news-and-events/events/others/2020/nansen-neuroscience-l...
 
Description Keynote/Invited Speaker - 8th Annual German Stem Cell Network Conference - Bertie Göttgens 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The conference will cover novel and latest findings in stem cell biology. It continues to foster interactions between researchers working on different types of stem cells, including pluripotent stem cells, adult stem cells, stem cells in development, stem cells in aging and cancer stem cells. Bertie was one of five invited keynote speakers, and he presented a lecture entitled "Development and maintenance of the blood system."
Year(s) Of Engagement Activity 2020
URL https://gscn-conferences.org/previous-gscn-conferences/gscn-conference-2020/program-and-speakers
 
Description Organiser - Molecular Haemopoiesis 23 - Tony Green 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The Molecular Haemopoiesis Meeting, which was initiated 23 years ago, is an annual gathering of the UK and European research communities studying blood cell development, with a particular focus on blood stem cell biology, developmental haematopoiesis, gene regulation and leukaemia. The meeting is organised by Professor Tony Green from the University of Cambridge, Professor Katrin Ottersbach from the University of Edinburgh, Professor Thomas Milne from the Weatherall Institute for Molecular Medicine in Oxford and Professor Dominique Bonnet from the Francis Crick Institute.
Year(s) Of Engagement Activity 2020
URL https://www.stemcells.cam.ac.uk/whats-on/molecular-haemopoiesis-23
 
Description Organiser - Stem Cells UK 2020 - Tony Green 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This one day meeting aims to bring together stem cell researchers from across the UK to share research ideas, forge collaborations and meet friends old and new.
Year(s) Of Engagement Activity 2020
URL https://www.stemcells.cam.ac.uk/whats-on/scuk
 
Description PSC Support Ask The Expert Q&A - Fotis Sampaziotis 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Online session with patient charity to discuss research and answer questions, livestreamed online.
Year(s) Of Engagement Activity 2021
URL https://www.pscsupport.org.uk/dr-fotios-sampaziotis-recording-available/
 
Description Physical and Virtual Exhibit for Cambridge Rare Disease Network RAREfest 2020 - Giovanna Mantica 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact RAREfest 2020 is an award winning festival that is as unique as the patients it champions. Events and workshops feature the brightest minds in rare disease research, the innovators of life-changing technologies, the pioneers in rare disease medicine and the patients whose powerful voices must be heard. The Cambridge Stem Cell Institute hosts an exhibit called 'Cambridge Stem Cell Institute: Stem Cells and You' through which attendees can learn more about laboratory processes and aspirations.
Year(s) Of Engagement Activity 2020
URL https://www.camraredisease.org/wp-content/uploads/2020/11/RAREfest20-Agenda.pdf
 
Description Plenary Speaker - CamBioScience Cerebral Organoids Course and 3D Cell Models Symposium - Joo-Hyeon Lee 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact We have developed a cerebral organoids course to empower scientists with this revolutionary technology. Using human pluripotent stem cells to create in vitro cerebral organoids allows the study of neural developmental mechanisms in human. They can also be used to understand the roots of human neurological diseases. Cerebral organoids can indeed be used in experiments where current in vitro methods are too simple. Therefore, they are more human applicable than rodent or other mammalian models.
Year(s) Of Engagement Activity 2020
URL https://www.cambioscience.com/2019/11/13/cerebral-organoids-course-26-28-october-2020/
 
Description Poetry workshops with Parkinson's UK - with several CSCI scientists 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact A series of poetry workshops with Parkinson's patients and stem cell researchers over six weeks, providing an opportunity to talk openly about, and write poetry reflecting, their lived experience of research and disease.
Several CSCI Scientist were involved in this project:
Shaline Fazal; Sophie Skidmore (Barker Group)
Jaana Bagri (Huntly Group)
Dominika Dziedzicka (Vallier Group)
Year(s) Of Engagement Activity 2021
 
Description Profile for University of Cambridge's 'Women in STEM' Webpage Series - Oluwaseun Ogundele 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Oluwaseun Ogundele is a research assistant in the Hendrich Lab at the Wellcome-MRC Cambridge Stem Cell Institute. Here, she tells us about her work studying the body's master cells and their role in disease, meeting Nobel Prize winners, and how she's using social media to increase the visibility of women of colour working in STEM fields.
Year(s) Of Engagement Activity 2020
URL https://www.cam.ac.uk/research/news/women-in-stem-oluwaseun-ogundele
 
Description Stem Cells 3 - CSCI were joint organisers of this public online event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Anthony Green (Director of CSCI) was a joint organiser of the event, working together with the Francis Crick Institute, the Centre for Regenerative Medicine, the DPAG Oxford and the London Stem Cell Network.
Stem Cells UK 3 was one day event, the third annual event of its kind and will feature a full day of talks from leading stem cell experts, including from our own CSCI scientists, Maria Alcolea and Robin Franklin.
Year(s) Of Engagement Activity 2019,2020,2021
URL https://www.stemcells.cam.ac.uk/events/stem-cells-uk-3
 
Description Story on Cambridge University Research page: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact Story on Cambridge University Research page: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage
Year(s) Of Engagement Activity 2021
URL https://www.cam.ac.uk/research/news/lab-grown-beating-heart-cells-identify-potential-drug-to-prevent...
 
Description Story on Cambridge University Research page: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact Story on Cambridge University Research page: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage
Year(s) Of Engagement Activity 2021
URL https://www.cam.ac.uk/research/news/lab-grown-mini-bile-ducts-used-to-repair-human-livers-in-regener...
 
Description Testimonial for NHS Blood and Transplant's 'R&D' Blog - Souradip Mookerjee 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact With this series of blogs, experts in haematology and stem cell biology provide insights into the research that NHS Blood and Transplant are working on to improve patient and donor care. Mr Souradip Mookerjee is an MB/PhD student in Dr Cedric Ghevaert's Lab at the University of Cambridge, working on the translational research of making platelets from stem cells.
Year(s) Of Engagement Activity 2020
URL https://www.nhsbt.nhs.uk/research-and-development/rd-blog/modern-day-alchemy-in-vitro-derived-platel...
 
Description The Perse School (Cambridge, UK) 'STEM: Stem Cell Special' School Visit, 28 February 2020 - Khalil Rawji and Celine Labouesse 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Celine Labouesse and Khalil Rawji participated in a discussion with Upper and Sixth Form students at The Perse School (Cambridge, UK) regarding Stem Cell Biology and careers in stem cell research.
Year(s) Of Engagement Activity 2020
URL https://www.perse.co.uk/calendar/
 
Description Trinity College, University of Cambridge 'Women in STEM' Virtual Event 2020 - Aditi Vedi 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact Target group: Year 12 state schooled women and non-binary people studying the sciences to A-Level or equivalent standard. A virtual day in the life of a Cambridge undergraduate studying STEM: course overviews, mock supervisions and lectures, and the chance to speak with and ask questions to students and staff studying STEM subjects across the university.
Year(s) Of Engagement Activity 2020
URL https://www.trin.cam.ac.uk/access/outreach-during-covid-19/
 
Description Virtual Presentation Hosted by University of Cambridge's Lucy Cavendish College - Sanjay Sinha 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact About this Event: Dr Sinha will explain the power of stem cells and how they make huge differences in how we understand and treat a range of different heart and blood vessel diseases. He will also cover a wide range of topics from 'disease-in-a-dish' approaches to how to repair damaged hearts to testing new treatments for Covid-19. About the speaker: Dr Sanjay Sinha is a British Heart Foundation Senior Research Fellow and a Reader at the University of Cambridge. He completed medical training in Cambridge, followed by a PhD in Manchester. Dr Sinha then carried out post-doctoral studies in the USA before founding his group within the Wellcome-MRC Cambridge Stem Cell Institute. He has established new ways to use human stem cells to aid developmental studies and generate human models of vascular diseases, in particular Marfan syndrome. He is also investigating novel techniques to regenerate the damaged heart. Dr Sinha is also a Cardiologist and he combines his research work with clinical duties at Addenbrooke's Hospital, where he treats patients with a wide variety of cardiovascular diseases.
Year(s) Of Engagement Activity 2020
URL https://www.eventbrite.co.uk/e/livefromlucy-with-dr-sanjay-sinha-tickets-129278574697#